As science and technology swiftly advances, the development of cell and gene therapies has accelerated with more than 2,000 clinical programs around the world and a projected 25% growth rate in the next five years. With this grown comes a myriad of challenges, including rapidly evolving multi-stakeholder requirements, and logistical considerations for study planning and delivery, mandated long-term follow-up of patients -- to name just a few.
Having supported more than 150 cell and gene therapy programs during the past five years, we understand and know the challenges you will face – generating the scientific evidence for your novel technologies and navigating the complex global regulatory landscape to maximize your products’ success and bring these new and innovative therapies to patients.
Meet with us to discuss your cell and gene therapy development challenges.
Product Development with the End-in-Mind: How Commercial Realities Should Inform Your Clinical & Evidence Generation Programs
January 18 | 1:30pm ET
Pete Robinson, Head of Cell & Gene Therapy Development Engine